

# UC Santa Cruz

## UC Santa Cruz Previously Published Works

### Title

Strict Regiospecificity of Human Epithelial 15-Lipoxygenase-2 Delineates Its Transcellular Synthesis Potential

### Permalink

<https://escholarship.org/uc/item/2mr4h0hk>

### Journal

Biochemistry, 55(20)

### ISSN

0006-2960

### Authors

Green, Abigail R  
Barbour, Shannon  
Horn, Thomas  
[et al.](#)

### Publication Date

2016-05-24

### DOI

10.1021/acs.biochem.5b01339

Peer reviewed



Published in final edited form as:

*Biochemistry*. 2016 May 24; 55(20): 2832–2840. doi:10.1021/acs.biochem.5b01339.

## Strict Regiospecificity of Human Epithelial 15-Lipoxygenase-2 Delineates Its Transcellular Synthesis Potential

Abigail R. Green, Shannon Barbour, Thomas Horn, Jose Carlos, Jevgenij A. Raskatov, and Theodore R. Holman\*

Department Chemistry and Biochemistry, University of California at Santa Cruz, 1156 High Street, Santa Cruz, California 95064, United States

### Abstract

Lipoxins are an important class of lipid mediators that induce the resolution of inflammation and arise from transcellular exchange of arachidonic acid (AA)-derived lipoxygenase products. Human epithelial 15-lipoxygenase-2 (h15-LOX-2), the major lipoxygenase in macrophages, has exhibited strict regiospecificity, catalyzing only the hydroperoxidation of carbon 15 of AA. To determine the catalytic potential of h15-LOX-2 in transcellular synthesis events, we reacted it with the three lipoxygenase-derived monohydroperoxy-eicosatetraenoic acids (HPETE) in humans: 5-HPETE, 12-HPETE, and 15-HPETE. Only 5-HPETE was a substrate for h15-LOX-2, and the steady-state catalytic efficiency ( $k_{\text{cat}}/K_{\text{m}}$ ) of this reaction was 31% of the  $k_{\text{cat}}/K_{\text{m}}$  of AA. The only major product of h15-LOX-2's reaction with 5-HPETE was the proposed lipoxin intermediate, 5,15-dihydroperoxy-eicosatetraenoic acid (5,15-diHPETE). However, h15-LOX-2 did not react further with 5,15-diHPETE to produce lipoxins. This result is consistent with the specificity of h15-LOX-2 despite the increased reactivity of 5,15-diHPETE. Density functional theory calculations determined that the radical, after abstracting the C10 hydrogen atom from 5,15-diHPETE, had an energy 5.4 kJ/mol lower than that of the same radical generated from AA, demonstrating the facility of 5,15-diHPETE to form lipoxins. Interestingly, h15-LOX-2 does react with 5*S*,6*R*-diHPETE, forming Lipoxin<sub>A4</sub>, indicating the gemdiol does not prohibit h15-LOX-2 reactivity. Taken together, these results demonstrate the strict regiospecificity of h15-LOX-2 that circumscribes its role in transcellular synthesis.

### Graphical abstract


\*Corresponding Author: holman@ucsc.edu.

#### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.biochem.5b01339. Supplemental Figures S1, S2, and S3 (PDF)

#### Notes

The authors declare no competing financial interest.



The acute inflammatory response is essential for host defense from pathogens or injury and is typically stimulated by lipid autacoids that recruit leukocytes to the affected area. The recruited leukocytes then release more lipid autacoids and other signaling molecules to either amplify the inflammatory response or resolve it.<sup>1</sup> The regulation of this response and its resolution are crucial for homeostasis, as uncontrolled or chronic inflammation can result in a number of diseases, including atherosclerosis,<sup>2–4</sup> diabetes,<sup>5,6</sup> periodontal disease,<sup>7</sup> autoimmune disorders,<sup>8</sup> and cancer.<sup>9–13</sup>

Although many factors contribute to the overall inflammatory response and resolution, an important class of regulatory molecules, the eicosanoids, has demonstrated the ability to recruit neutrophils and macrophages, induce thrombus formation, regulate vasodilation/constriction, and even contribute to apoptosis.<sup>9,14–16</sup> These eicosanoids are derived from arachidonic acid (AA) in leukocytes and other cells by cyclooxygenases or lipoxygenases. In humans, there are six known lipoxygenases (LOX): leukocyte 5-LOX (h5-LOX), platelet 12-LOX (h12-LOX), 12R-LOX, epidermal LOX-3, reticulocyte 15-LOX-1 (h15-LOX-1 or 12/15-LOX), and epithelial 15-LOX-2 (h15-LOX-2). Each LOX is classified by the carbon position of AA that is predominately oxygenated and the tissue in which each LOX was originally found.<sup>14</sup> Lipoxygenases are non-heme iron-containing dioxygenases that synthesize eicosanoids by sequential hydroperoxidation of polyunsaturated fatty acids (PUFAs), either individually or in concert transcellularly.<sup>17–22</sup> The lipoxygenase products that are of particular interest in this study are the lipoxins, which mediate inflammation catabasis via vasodilation/constriction, suppression of leukotriene-mediated inflammation, M2 macrophage recruitment, and effects on cytokine signaling.<sup>8,23,24</sup> These lipoxins (lipoxygenase interaction products) are trihydroxylated eicosatetraenoic acids that result from the transcellular exchange of lipoxygenase products.<sup>21</sup> Several transcellular exchange routes have been demonstrated to produce lipoxins *in vivo* and *in vitro* (Scheme 1).<sup>18,21,22,25–31</sup> The first route starts with 15-hydroperoxy-5*Z*,8*Z*,10*Z*,13*E*-eicosatetraenoic acid (15-HPETE), produced by either of the h15-LOXs in reticulocytes, macrophages, endothelial cells, etc.<sup>17,21,26,32–34</sup> This 15-HPETE can then be converted into 5*S*,15*S*-dihydroperoxy-6*E*,8*Z*,10*Z*,13*E*-eicosatetraenoic acid (5,15-diHPETE) by h5-LOX in neutrophils or other cells. The resulting 5,15-diHPETE can be further epoxidated by h5LOX to form 5*S*-*trans*-5,6-oxido-15*S*-hydroperoxy-7*E*,9*E*,11*Z*,14*Z*-eicosatetraenoic acid (15*S*-hydroperoxy-LTA<sub>4</sub>). 15*S*-hydroperoxy-LTA<sub>4</sub> can be hydrolyzed by soluble epoxide hydrolase and reduced by glutathione peroxidase (GP) to form 5*S*,6*R*,15*S*-trihydroxy-7*E*,9*E*,11*Z*,13*E*-eicosatetraenoic acid (LipoxinA<sub>4</sub> (LxA<sub>4</sub>)).<sup>21,26,34–36</sup> Due to the instability of the 5,6-epoxide on 15*S*-hydroperoxy-LTA<sub>4</sub>, this intermediate can also be hydrolyzed nonenzymatically at carbon 6 and reduced by GP to form 5*S*,6*S*,15*S*-trihydroxy-7*E*,9*E*,11*Z*,

13*E*-eicosate-traenoic acid or at carbon 14 to yield 5*S*,14*R*(or *S*),15*S*-trihydroxy-6*E*,8*E*,10*E*,12*E*-eicosatetraenoic acid (LxB<sub>4</sub>, all *trans* isomers).<sup>26,30</sup> A similar lipoxin pathway involving a 5,15-diHPETE intermediate starts instead with 5-hydroperoxy-6*E*,8*Z*,11*Z*,14*Z*-eicosatetraenoic acid (5-HPETE) from h5-LOX.<sup>21,26</sup> This 5-HPETE can then react with h15-LOX-1 to produce 5,15-diHPETE. This 5,15-diHPETE can then be epoxidated by h12-LOX or h15-LOX-1 to form 5*S*-hydroperoxy-15*S-trans*-14,15-oxido-6*E*,8*Z*,10*E*,12*E*-eicosatetraenoic acid. This product can be hydrolyzed by soluble epoxide hydrolase and reduced by GP to form 5*S*,14*R*,15*S*-trihydroxy-6*E*,8*Z*,10*E*,12*E*-eicosatetraenoic acid (LipoxinB<sub>4</sub>(LxB<sub>4</sub>)).<sup>21,26,31,37,38</sup> Also, as with 15*S*-hydroperoxy-LTA<sub>4</sub>, the 14,15-epoxide is not stable and can be hydrolyzed non-enzymatically to form 5*S*,14*S*,15*S*-trihydroxy-6*E*,8*Z*,10*E*,12*E*-eicosatetraenoic acid or 5*S*,6*R*(or *S*),15*S*-trihydroxy-7*E*,9*E*,11*E*,13*E*-eicosatetraenoic acid (LxA<sub>4</sub>, all *trans* isomers).<sup>31,37-39</sup> Yet another route can be initiated by h5-LOX's major product, 5*S-trans*-5,6-oxido-7*E*,9*E*,11*Z*,14*Z*-eicosatetraenoic acid (LTA<sub>4</sub>), which can then be converted into LxA<sub>4</sub> via hydroperoxidation by either h15-LOX-1 in reticulocytes or h12-LOX in platelets; hydrolysis of the epoxide nonenzymatically or by epoxide hydrolase and reduction by GP are needed to convert the resulting 15*S*-hydroperoxy-LTA<sub>4</sub> into the final product LxA<sub>4</sub>.<sup>18,22,27,28</sup> Additionally, LTA<sub>4</sub> compounds that are not hydrolyzed to their main product (5*S*,12*R*-dihydroxy-6*Z*,8*E*,10*E*,14*Z*-eicosatetraenoic acid (LTB<sub>4</sub>)) can also be converted to 5*S*,6*R*-dihydroxy-7*E*,9*E*,11*Z*,14*Z*-eicosatetraenoic acid (5,6-diHETE) by soluble epoxide hydrolase or non-enzymatic hydrolysis to either 5*S*,6*R*-diHETE or 5*S*,6*S*-diHETE.<sup>18,29,40,41</sup> 5*S*,6*R*-diHETE can then react with h12-LOX to generate LxA<sub>4</sub>, while 5*S*,6*S*-diHETE will generate 6*S*-LxA<sub>4</sub>.<sup>18</sup> Finally, lipoxins can be generated by the 6*R*-oxygenase and 14*R*-oxygenase activities of h5-LOX and h12-LOX, which are not illustrated here.<sup>31,40</sup> Thus, as their name implies, lipoxins arise from the many possible exchanges of lipoxygenase AA products.

In this study, we aim to elucidate the potential of h15-LOX-2 to synthesize lipoxins. h15-LOX-2 was originally discovered as a distinct LOX isoform in epithelial cells and exhibited product regiospecificity that set it apart from h15-LOX-1.<sup>42</sup> Principally, h15-LOX-2 converts AA into 15-HPETE exclusively, producing none of the 12-HPETE product seen in the h15-LOX-1 reaction with AA (Scheme 2). On the basis of its original expression patterns, h15-LOX-2 was not considered as a key player in atherosclerosis and other vascular diseases, but recent studies have revealed that h15-LOX-2 is the major lipoxygenase expressed in macrophages, is found in high abundance in atherosclerotic plaques, and is induced by hypoxia and other inflammation factors.<sup>2,4,43</sup> Additionally, using macrophages from cystic fibrosis patients, the Urbach lab established a correlation between the mRNA levels of h15-LOX-2 and the ratio of two key opposing lipid mediators: LxA<sub>4</sub> and LTB<sub>4</sub>.<sup>32</sup> Given this fresh perspective, the role of h15-LOX-2 in transcellular synthesis may be antagonistic to the leukotriene-mediated inflammatory pathways of h5-LOX, but its direct biosynthetic potential has not been evaluated.

Previous work has demonstrated the abilities of porcine 5-LOX, porcine 15-LOX-1, and h12-LOX to turn over AA secondary metabolites (e.g., mono- and dihydroperoxy-eicosatetraenoic acids) into lipoxins.<sup>17,22,31,34</sup> Additionally, in studies by Green<sup>20</sup> and Zhao et al.,<sup>44</sup> human keratinocytes containing 15-lipoxygenase activity were shown to turn over 5-HETE into 5,15-diHETE. However, no study to date has demonstrated the potential of h15-

LOX-2 to synthesize lipoxins or determined its kinetics with AA secondary metabolites. In this work, we investigated both the kinetics and the in vitro product profile of h15-LOX-2 with a variety of oxylipins and defined the catalytic bounds of h15-LOX-2.

## EXPERIMENTAL PROCEDURES

### Chemicals

The lipid mass spectrometry standards for 5,15-diHETE, 5,6-diHETE, LxA<sub>4</sub>, and LxB<sub>4</sub> were purchased from Cayman Chemical. AA was purchased from Nu Chek Prep, Inc., and used to synthesize 5-HPETE, 5-HETE, 12-HPETE, 15-HPETE, 13*S*-hydroxy-9*Z*,11*E*-octadecadienoic acid (13-HODE), 13*S*-hydroperoxy-9*Z*,11*E*-octadecadienoic acid (13-HPODE), and 5*S*,5,15-diHPETE as follows. Syntheses of 5-HPETE, 5-HETE, 12-HPETE, 15-HPETE, 13-HODE, and 13-HPODE were performed as previously described.<sup>45–47</sup> 5,15-diHPETE was synthesized from 15-HPETE as follows. Twenty micromolar 15-HPETE was reacted in 1 L of 50 mM HEPES (pH 7.5), 50 mM NaCl, and 100  $\mu$ M EDTA (buffer A) with 200  $\mu$ M ATP and 1 g of h5-LOX ammonium sulfate precipitate, prepared as previously described.<sup>45</sup> This reaction was monitored at 254 nm to completion, quenched with 0.5% (v/v) glacial acetic acid, extracted with 1 L of DCM, and evaporated to dryness. 5,15-diHPETE was then purified via high-performance liquid chromatography (HPLC) on a Higgins Haisil semipreparative (5  $\mu$ m, 250 mm  $\times$  10 mm) C18 column with an isocratic elution of 50/50 acetonitrile/water. Purity was assessed via liquid chromatography–mass spectrometry to be greater than 90%.

### Expression and Purification of h15-LOX-2

Over-expression and purification of wild-type h15-LOX-2 was performed as previously described.<sup>48</sup> The purity of the enzyme was assessed by SDS gel electrophoresis to be greater than 85%. Metal content was assessed on a Finnigan inductively coupled plasma-mass spectrometer (ICP-MS) via comparison with an iron standard solution. Cobalt-EDTA was used as an internal standard.

### Analysis of h15-LOX-2 Products from 5-HETE, 5-HPETE, 12-HPETE, 15-HPETE, 5,6-diHETE, and 5,15-diHPETE

h15-LOX-2 (0.6 pmol) was reacted in 6 mL of 25 mM HEPES (pH 7.5) at ambient temperature with 10  $\mu$ M oxylipin (5-HETE, 5-HPETE, 12-HPETE, 15-HPETE, 5,15-diHPETE, or 5,6-diHETE) for 1 h, quenched with 0.5% glacial acetic acid, extracted with 6 mL of DCM, reduced with trimethylphosphite, and evaporated under a stream of N<sub>2</sub> to dryness. The reaction mixtures were then reconstituted in 30  $\mu$ L of methanol, further diluted with 60  $\mu$ L of 0.1% formic acid in water, and analyzed via LC-MS/MS. Control reactions without h15-LOX-2 were run to ensure that the products formed were not a result of oxylipin degradation. Additional reactions were performed for 1 and 10 min to determine relative turnover rates of the secondary substrates. Chromatographic separation was performed on a Dionex UltiMate 3000 UHPLC with a C<sub>18</sub> column (Phenomenex Kinetex, 1.7  $\mu$ m, 150 mm  $\times$  2.1 mm). The autosampler was held at 4 °C, and the injection volume was 20  $\mu$ L. Mobile phase A consisted of water with 0.1% (v/v) formic acid, and mobile phase B consisted of acetonitrile with 0.1% formic acid. The flow rate was 0.350 mL/min.

The initial condition (40% mobile phase B) was ramped up to 45% over 19 min. Mobile phase B was then ramped up to 75% over an additional 19 min and returned to 40% to equilibrate for 10 min. The chromatography system was coupled to a Velos Pro linear ion trap (Thermo Scientific) for mass analysis. Analytes were ionized via heated electrospray ionization with  $-4.0$  kV spray voltage and 35, 10, and 0 arbitrary units for sheath, auxiliary, and sweep gas, respectively. The radiofrequency amplitude of the S-Lens was 52.5%, and the probe and capillary temperatures were 45 and 350 °C, respectively. All analyses were performed in negative ionization mode at the normal resolution setting. MS<sup>2</sup> was performed at 35% normalized collision energy in a targeted manner with a mass list containing the following  $m/z$  ratios  $\pm 0.1$ : 319.2, 335.2, 351.2, and 367.2. The UV detectors used were Thermo PDA Plus and Dionex Ultimate-3000 DAD. The DAD is slightly blue-shifted and not as sensitive as the Thermo PDA Plus, while the PDA Plus can lose small spectral features by its spectrum averaging. Both detectors were used for identification in all cases, but the most informative spectrum for each is included in the figures. We identified the products by matching retention times, UV spectra, and fragmentation patterns to those of known standards (Figure S1).

### Steady-State Kinetics of h15-LOX-2 with 5-HETE and 5-HPETE

Reactions were performed at ambient temperature in a quartz cuvette containing 2 mL of buffer A with substrate (AA, 5-HPETE, or 5-HETE). AA concentrations were varied from 0 to 29  $\mu\text{M}$ ; 5-HPETE concentrations were varied from 0 to 35  $\mu\text{M}$ , and 5-HETE concentrations were varied from 0 to 32  $\mu\text{M}$ . Higher concentrations were avoided to prevent the formation of micelles. We determined the concentration of AA by measuring the amount of 15-HPETE produced from complete reaction with soybean lipoxygenase-1 (sLO-1). The concentrations of 5-HETE and 5-HPETE were determined from the absorbance at 234 nm. Reactions were initiated by the addition of 0.2 pmol of h15-LOX-2 and monitored on a Hewlett-Packard 8453 UV-vis spectrophotometer. Product formation was determined by the change in absorbance at 234 nm for 15-HPETE ( $\epsilon_{234\text{nm}} = 25000 \text{ M}^{-1} \text{ cm}^{-1}$ ) and 254 nm for 5,15-diHPETE. The absorbance maximum for 5,15-diHPETE (247 nm) was not used due to the overlap from the decaying 5-HPETE absorbance at 234 nm. The molar extinction coefficient for 5,15-diHPETE at 254 nm was derived semiempirically from the literature value ( $\epsilon_{247\text{nm}} = 33500 \text{ M}^{-1} \text{ cm}^{-1}$  in methanol)<sup>49</sup> and standard dilutions to be  $24300 \pm 30 \text{ M}^{-1} \text{ cm}^{-1}$  in methanol and  $21900 \pm 700 \text{ M}^{-1} \text{ cm}^{-1}$  in buffer A. KaleidaGraph (Synergy) was used to fit initial rates (at less than 20% turnover) as well as the second order derivatives ( $k_{\text{cat}}/K_{\text{m}}$ ) to the Michaelis–Menten equation for the calculation of kinetic parameters.

### Computational Methods

Density functional theory (DFT) calculations were performed using the Gaussian 09 software package<sup>50</sup> with a combination of the Becke exchange functional (B)<sup>51</sup> and the Lee–Yang–Parr correlation functional (LYP).<sup>52,53</sup> The 6-311G(d,p) basis set was employed to describe the system.<sup>54</sup> No symmetry constraints were applied during the geometry optimization, and the obtained minimum was confirmed by frequency calculation (no imaginary frequencies). Low-energy conformers were obtained through manual adjustment of dihedral angles with subsequent reoptimization. Higher energy conformers (typically 4–5 kcal/mol higher in energy) are not discussed.

## RESULTS AND DISCUSSION

### Product Profiles of h15-LOX-2 with AA and Monohydro(pero)xy-eicosatetraenoic Acids

In previous studies, h15-LOX-2 has demonstrated complete regioselectivity in contrast to h15-LOX-1.<sup>42,55,56</sup> In particular, h15-LOX-1 can produce both 15-HPETE and 12-HPETE from AA by hydrogen abstraction at the C13 and C10 positions, respectively<sup>55,56</sup> (Scheme 2). On the other hand, h15-LOX-2 has been shown to produce only 15-HPETE from AA, selectively abstracting only the C13 hydrogen atom.<sup>42</sup> In our experiments, we observed this selectivity as well. Reactions of h15-LOX-2 with AA produced only 15-HPETE (data not shown), and no further reaction was seen with 15-HPETE (Figure S3A). Despite the availability of a C13 hydrogen atom to abstract and a C15 to oxygenate, h15-LOX-2 did not react with 12-HPETE (Figure S3B). This is not surprising given that the C13 hydrogen atoms are no longer bisallylic due to the location of the C12 hydroperoxy moiety. Additionally, this hydroxyl may also block the proper insertion of 12-HPETE into the active site. Despite h15-LOX-2's lack of reactivity with 12-HPETE and 15-HPETE, we tested these HPETEs to ensure that no reactions were available via nontraditional binding modes. However, when h15-LOX-2 was reacted with 5-HPETE, it produced 5,15-diHETE (Figure 1). 5,15-diHETE has been observed in previous reactions with keratinocytes containing 15-lipoxygenase activity<sup>20,44</sup> and was suggested to be an intermediate in lipoxin biosynthesis.<sup>17,20</sup>

### Steady-State Kinetics of 5-HPETE and Formation of the Lipoxin Intermediate 5,15-diHPETE

In addition to demonstrating h15-LOX-2's ability to convert 5-H(P)ETE to 5,15-diH(P)ETE, we determined the catalytic efficiency of this turnover. The steady-state kinetic parameters of h15-LOX-2 were obtained for AA, 5-HETE, and 5-HPETE (Table 1). The absolute  $k_{\text{cat}}$  (catalytic rate) and  $k_{\text{cat}}/K_{\text{m}}$  (catalytic efficiency) for h15-LOX-2 with AA (normalized to metal content) were  $0.64 \pm 0.02 \text{ s}^{-1}$  and  $0.16 \pm 0.02 \mu\text{M}^{-1} \text{ s}^{-1}$ , respectively, which corroborates previously reported values.<sup>47</sup> Kinetic  $k_{\text{cat}}$  and  $k_{\text{cat}}/K_{\text{m}}$  parameters of the secondary metabolites are reported relative to AA. As reported in Table 1, h15-LOX-2 displayed  $k_{\text{cat}}$  values for 5-HETE and 5-HPETE greater than that for AA, but the  $K_{\text{m}}$  (Michaelis constant) values for these secondary metabolites were much higher than that for AA. The net result was a lower catalytic efficiency ( $k_{\text{cat}}/K_{\text{m}}$ ) relative to AA for 5-HETE and 5-HPETE (25% and 31%, respectively). These relative  $k_{\text{cat}}/K_{\text{m}}$  values are large, considering that the relative  $k_{\text{cat}}/K_{\text{m}}$  value of h5-LOX with 5-HPETE is 2% of its catalytic efficiency with AA.<sup>45</sup> These results can be explained by the fact that h15-LOX-2 is abstracting its "native" hydrogen atom from 5-HETE (C13), while h5-LOX abstracts the less-preferred hydrogen (C10 versus C7 for AA). Nonetheless, the fact that the catalytic efficiency of h15-LOX-2 with 5-HETE is large indicates the minor effect the hydroxyl of C5 has on catalysis.

### Energetics of C10 Abstraction from 5,15-diHPETE

Considering the potential of 5,15-diHPETE as a lipoxin intermediate, we modeled its reactivity through homolytic CH bond cleavage by employing DFT methods. We calculated the energy required for C10 hydrogen abstraction and the resulting radical stabilization. DFT calculations were performed on model compounds (Figure 2, **m1**–**m3**) that correspond to the conjugated systems of AA (**m1**), 5(or 15)-HPETE (**m2**), and 5,15-diHPETE (**m3**). The



simplest case, model **m1**, contains four alkene moieties that are separated with methylene spacers and terminated with methyl groups. The two conceivable hydrogen abstraction pathways, denoted A (C10 abstraction) and B (C7 or C13 abstraction), both yield radical systems that can delocalize over five carbon atoms and are uphill by 67.2 kcal/mol, independent of position. In model **m2**, the abstraction pathway A leads to a radical that can delocalize over seven carbon centers, and the intermediate is calculated to have an energy 3.0 kcal/mol (64.2 kcal/mol) lower than that of the intermediate generated through pathway B. The latter is practically identical in stability to the radical intermediates computed for model **m1** (67.1 kcal/mol). Finally, model **m3** yielded a fully conjugated radical (nine carbon centers) upon hydrogen atom abstraction, and the bond dissociation energy was lowered by an additional 2.5 kcal/mol (61.8 kcal/mol). As noted in Computational Methods, these energies correspond to the lowest energy conformers in each case, and the conformations to which these molecules would be constrained in the active site may differ. Even so, the ability of the C10 radical to extend over nine carbon centers instead of seven or five lends to the ease of hydrogen atom abstraction and subsequent epoxidation in which the 5,15-diHETE intermediate could be converted into lipoxins.

### Product Profiles of h15-LOX-2 with Dihydro(pero)xy-eicosatetraenoic acids

In view of this lowered energy for C10 hydrogen atom abstraction, we reasoned that h15-LOX-2 may be capable of lipoxin formation from 5,15-diHPETE. Thus, we reacted h15-LOX-2 with 5,15-diHPETE to determine if this lowered bond energy allows for an exception to h15-LOX-2's stringent regiospecificity; however, h15-LOX-2 continued to demonstrate strict C13 hydrogen atom abstraction. h15-LOX-2 did not react with 5,15-diHPETE (Figure 3) to form either of the lipoxins. Although a small peak with the same retention time and parent mass as LxA<sub>4</sub> was observed in the h15-LOX-2 reaction, the MS<sup>2</sup> spectra did not match those of LxA<sub>4</sub>. There was, however, a trace amount of an unknown product produced by h15-LOX-2 in both its reaction with 5-HPETE and 5,15-diHPETE, which is consistent with a previous report on 15-lipoxygenase activity.<sup>20</sup> This unidentified product was determined not to be LxB<sub>4</sub> or LxA<sub>4</sub> due to its longer retention time and UV-vis absorbance spectrum (Figure S4). As a positive control, h15-LOX-1 was reacted with 5,15-diHPETE and was able to form LxB<sub>4</sub>.<sup>17,26</sup> With the consideration that h15-LOX-2 has an allosteric site for 13-HODE and is readily activated by 13-HPODE,<sup>57,58</sup> h15-LOX-2 was reacted with 5,15-diHPETE in the presence of 10 μM 13-HPODE. However, even with excess 13-HPODE, h15-LOX-2 was unable to generate lipoxins from this 5,15-diHPETE intermediate (data not shown). In other words, h15-LOX-2 continues to demonstrate regiospecificity for the C13 hydrogen abstraction and C15 oxygen attack even with the lowered abstraction energy for 5,15-diHPETE.

This regiospecificity does not, however, preclude h15-LOX-2 from the formation of lipoxins in light of the h5-LOX products available (Scheme 1).<sup>18,22</sup> Given cellular conditions, the second major product of human and porcine h5-LOX is LTA<sub>4</sub>,<sup>59-62</sup> which is unstable in water and easily hydrolyzed into various 5,6-diHETE epimers nonenzymatically or by epoxide hydrolase.<sup>18,29</sup> This is a minor pathway in the cell, however, with the main hydrolysis product being LTB<sub>4</sub> formed by LTA<sub>4</sub> hydrolase.<sup>63,64</sup> We demonstrated that h15-LOX-2 reacts with 5-HPETE, and considering that the locations of the hydroperoxy and



epoxy moieties were far from the methyl end of 5,6-diHETE and LTA<sub>4</sub>, respectively, we suspected that h15-LOX-2 could generate LxA<sub>4</sub> from 5,6-diHETE and/or LTA<sub>4</sub>. Unfortunately, we could not test whether h15-LOX-2 could generate LxA<sub>4</sub> from LTA<sub>4</sub> because h15-LOX-2's in vitro catalytic efficiency is slower than LTA<sub>4</sub>'s in vitro hydrolysis rate in pH 7.4 buffer (~2.2 μM/s).<sup>65</sup> Currently, no in vitro technique exists that can stabilize LTA<sub>4</sub> and trap 15-hydroxy-LTA<sub>4</sub>, which makes the existence of 15-hydroxy-LTA<sub>4</sub> in lipoxin biosynthesis speculative. However, we were able to demonstrate that h15-LOX-2 does hydroperoxidate C15 of 5*S*,6*R*-diHETE to generate LxA<sub>4</sub> (Figure 4), and the relative rate of this reaction was 99.5% of h15-LOX-2's rate with 5-HPETE. Thus, the addition of a hydroxyl at C6 had little effect on the rate. With respect to LTA<sub>4</sub> reactivity, we speculate that because h15-LOX-2 generates LxA<sub>4</sub> from 5*S*,6*R*-diHETE, it most likely could convert LTA<sub>4</sub> to LxA<sub>4</sub> as 5,6-diHETE is bulkier and more polar than a 5,6-epoxide.

### Implications of the Findings: h15-LOX-2's Role in Transcellular Synthesis

With its expression in macrophages and endothelial and epithelial tissues, h15-LOX-2 has the potential to play a role in many inflammatory events involving transcellular syntheses. However, as observed in this study and previous studies, h15-LOX-2 has strict regiospecificity for C15 hydroperoxidation, which constrains its role in these transcellular syntheses. In particular, we found that h15-LOX-2 will not react with its own AA product (15-HPETE) or h12-LOX's AA product (12-HPETE). Additionally, h15-LOX-2 cannot generate LxB<sub>4</sub> from 5-HPETE or 5,15-diHPETE due to its inability to abstract a C10 hydrogen atom. However, h15-LOX-2 does generate 15-HPETE from AA, which can then be exchanged with h5-LOX to form lipoxins.<sup>26,30,31,39</sup> In addition, this study demonstrates that h15-LOX-2 can convert h5-LOX-derived pro-inflammatory mediators (5-HETE and 5,6-diHETE) into anti-inflammatory precursors (i.e., LxA<sub>4</sub>). This antagonism between h15-LOX-2 and h5-LOX may be an important switch between pro- and anti-inflammatory mediators in vivo, as demonstrated in studies of prostate cancer cells<sup>10-12</sup> and cystic fibrosis macrophages.<sup>32</sup> For example, 5-HETE has been implicated in the proliferation of prostate cancer,<sup>13,66,67</sup> and an increase in h15-LOX-2 expression results in decreased proliferation of prostate cancer cells.<sup>10-12</sup> Perhaps h15-LOX-2's efficient reaction with 5-HETE lends to the reduction of the cellular level of this compound and promotes antitumorigenic effects. In a similar vein, a more specific correlation was seen in macrophages of cystic fibrosis patients in which the ratio of LxA<sub>4</sub> to LTB<sub>4</sub> correlated directly with h15-LOX-2 mRNA levels.<sup>32</sup> This correlation lends credence to the "class-switching" ability of h15-LOX-2 in that LTA<sub>4</sub> can be converted to the potent inflammatory LTB<sub>4</sub> via LTA<sub>4</sub> hydrolase or to the potent anti-inflammatory LxA<sub>4</sub> via h15-LOX-2. In addition, h15-LOX-2 could convert 5,6-diHETE, which has demonstrated some inflammatory effects,<sup>68,69</sup> into LxA<sub>4</sub>. This directly demonstrates h15-LOX-2's ability to efficiently switch h5-LOX products into their anti-inflammatory counterparts. Altogether, the role that h15-LOX-2 plays in the complex network of pro-inflammatory and pro-resolving lipid mediators has yet to be fully understood, but we have demonstrated, at the enzymatic level, h15-LOX-2's ability to efficiently "class-switch" h5-LOX pro-inflammatory mediators into anti-inflammatory intermediates and delineated its potential to participate in transcellular syntheses.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

### Funding

This work was supported by NIH Grants NS081180 and GM56062.

## ABBREVIATIONS

<b>LOX</b>	lipoxygenase
<b>h15-LOX-2</b>	human epithelial 15-lipoxygenase-2
<b>h15-LOX-1</b>	human reticulocyte 15-lipoxygenase-1
<b>sLO-1</b>	soybean lipoxygenase-1
<b>5-LOX</b>	leukocyte 5-lipoxygenase
<b>12-LOX</b>	human platelet 12-lipoxygenase
<b>GP</b>	glutathione peroxidase
<b>AA</b>	arachidonic acid
<b>HETE</b>	hydroxy-eicosatetraenoic acid
<b>HPETE</b>	hydroperoxy-eicosatetraenoic acid
<b>diHETEs</b>	dihydroxy-eicosatetraenoic acids
<b>5-HETE</b>	5-hydroxy- 6 <i>E</i> ,8 <i>Z</i> ,11 <i>Z</i> ,14 <i>Z</i> -eicosatetraenoic acid
<b>5-HPETE</b>	5-hydroperoxy-6 <i>E</i> ,8 <i>Z</i> ,11 <i>Z</i> ,14 <i>Z</i> -eicosatetraenoic acid
<b>12-HPETE</b>	12-hydroperoxy-5 <i>Z</i> ,8 <i>Z</i> ,10 <i>E</i> ,14 <i>Z</i> -eicosatetraenoic acid
<b>15-HPETE</b>	15-hydroperoxy-5 <i>Z</i> ,8 <i>Z</i> ,10 <i>Z</i> ,13 <i>E</i> -eicosatetraenoic acid
<b>5,15-HETE</b>	5 <i>S</i> ,15 <i>S</i> -dihydroxy-6 <i>E</i> ,8 <i>Z</i> ,10 <i>Z</i> ,13 <i>E</i> -eicosatetraenoic acid
<b>5,15-diHPETE</b>	5,15-dihydroperoxy-6 <i>E</i> ,8 <i>Z</i> ,10 <i>Z</i> ,13 <i>E</i> -eicosatetraenoic acid
<b>5,6-diHETE</b>	5 <i>S</i> ,6 <i>R</i> -dihydroxy-7 <i>E</i> ,9 <i>E</i> ,11 <i>Z</i> ,14 <i>Z</i> -eicosatetraenoic acid
<b>LTA<sub>4</sub></b>	5 <i>S</i> - <i>trans</i> -5,6-oxido-7 <i>E</i> ,9 <i>E</i> ,11 <i>Z</i> ,14 <i>Z</i> -eicosatetraenoic acid
<b>LTB<sub>4</sub></b>	5 <i>S</i> ,12 <i>R</i> -dihydroxy-6 <i>Z</i> ,8 <i>E</i> ,10 <i>E</i> ,14 <i>Z</i> -eicosatetraenoic acid
<b>LipoxinA<sub>4</sub> (LxA<sub>4</sub>)</b>	5 <i>S</i> ,6 <i>R</i> ,15 <i>S</i> -trihydroxy-7 <i>E</i> ,9 <i>E</i> ,11 <i>Z</i> ,13 <i>E</i> -eicosatetraenoic acid

**LipoxinB<sub>4</sub> (LxB<sub>4</sub>)**      5*S*,14*R*,15*S*-trihydroxy-6*E*,8*Z*,10*E*,12*E*-eicosatetraenoic acid

## References


1. Kuehl FA, Egan RW. Prostaglandins, arachidonic acid and inflammation. *Science*. 1980; 210:978–984. [PubMed: 6254151]
2. Hulten LM, Olson FJ, Aberg H, Carlsson J, Karlstrom L, Boren J, Fagerberg B, Wiklund O. 15-Lipoxygenase-2 is expressed in macrophages in human carotid plaques and regulated by hypoxia-inducible factor-1 $\alpha$ . *Eur J Clin Invest*. 2010; 40:11–17. [PubMed: 19912316]
3. Gertow K, Nobili E, Folkersen L, Newman JW, Pedersen TL, Ekstrand J, Swedenborg J, Kühn H, Wheelock CE, Hansson GK, Hedin U, Haeggström JZ, Gabrielsen A. 12- and 15-lipoxygenases in human carotid atherosclerotic lesions: Associations with cerebrovascular symptoms. *Atherosclerosis*. 2011; 215:411–416. [PubMed: 21316676]
4. Rydberg EK. Hypoxia Increases LDL Oxidation and Expression of 15-Lipoxygenase-2 in Human Macrophages. *Arterioscler, Thromb, Vasc Biol*. 2004; 24:2040–2045. [PubMed: 15358603]
5. Weaver JR, Holman TR, Imai Y, Jadhav A, Kenyon V, Maloney DJ, Nadler JL, Rai G, Simeonov A, Taylor-Fishwick DA. Integration of pro-inflammatory cytokines, 12-lipoxygenase and NOX-1 in pancreatic islet beta cell dysfunction. *Mol Cell Endocrinol*. 2012; 358:88–95. [PubMed: 22502743]
6. Cole BK, Lieb DC, Dobrian AD, Nadler JL. 12- and 15-lipoxygenases in adipose tissue inflammation. *Prostaglandins Other Lipid Mediators*. 2013; 104–105:84–92.
7. Van Dyke TE, Serhan CN. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. *J Dent Res*. 2003; 82:82–90. [PubMed: 12562878]
8. Mangino MJ, Brounts L, Harms B, Heise C. Lipoxin biosynthesis in inflammatory bowel disease. *Prostaglandins Other Lipid Mediators*. 2006; 79:84–92. [PubMed: 16516812]
9. Greene ER, Huang S, Serhan CN, Panigrahy D. Regulation of inflammation in cancer by eicosanoids. *Prostaglandins Other Lipid Mediators*. 2011; 96:27–36. [PubMed: 21864702]
10. Suraneni M, Moore J, Zhang D, Badeaux M, Macaluso M, DiGiovanni J, Kusewitt D, Tang DG. Tumor-suppressive functions of 15-Lipoxygenase-2 and RB1CC1 in prostate cancer. *Cell Cycle*. 2014; 13:1798–1810. [PubMed: 24732589]
11. Tang S. Evidence That Arachidonate 15-Lipoxygenase 2 Is a Negative Cell Cycle Regulator in Normal Prostate Epithelial Cells. *J Biol Chem*. 2002; 277:16189–16201. [PubMed: 11839751]
12. Tang Y, Wang MT, Chen Y, Yang D, Che M, Honn KV, Akers GD, Johnson SR, Nie D. Downregulation of vascular endothelial growth factor and induction of tumor dormancy by 15-lipoxygenase-2 in prostate cancer. *Int J Cancer*. 2009; 124:1545–1551. [PubMed: 19089921]
13. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. *Cancer Res*. 2001; 61:6307–6312. [PubMed: 11522616]
14. Kuhn H, Banthiya S, van Leyen K. Mammalian lipoxygenases and their biological relevance. *Biochim Biophys Acta, Mol Cell Biol Lipids*. 2015; 1851:308–330.
15. Vijil C, Hermansson C, Jeppsson A, Bergström G, Hultén LM. Arachidonate 15-Lipoxygenase Enzyme Products Increase Platelet Aggregation and Thrombin Generation. *PLoS One*. 2014; 9:88546.
16. Lefler AM, Stahl GL, Lefler DJ, Brezinski ME, Nicolaou KC, Veale CA, Abe Y, Smith JB. Lipoxins A4 and B4: comparison of icosanoids having bronchoconstrictor and vasodilator actions but lacking platelet aggregatory activity. *Proc Natl Acad Sci U S A*. 1988; 85:8340–8344. [PubMed: 3186729]
17. Kuhn H, Wiesner R, Alder L, Fitzsimmons BJ, Rokach J, Brash AR. Formation of lipoxin B by the pure reticulocyte lipoxygenase via sequential oxygenation of the substrate. *Eur J Biochem*. 1987; 169:593–601. [PubMed: 3121318]
18. Tornhamre S, Gigou A, Edenius C, Lellouche JP, Lindgren JA. Conversion of 5,6-dihydroxyeicosatetraenoic-acids: A novel pathway for lipoxin formation by human platelets. *FEBS Lett*. 1992; 304:78–82. [PubMed: 1618303]

19. Wecksler AT, Kenyon V, Deschamps JD, Holman TR. Substrate Specificity Changes for Human Reticulocyte and Epithelial 15-Lipoxygenases Reveal Allosteric Product Regulation<sup>†</sup>. *Biochemistry*. 2008; 47:7364–7375. [PubMed: 18570379]
20. Green FA. Transformations of 5-HETE by activated keratinocyte 15-lipoxygenase and the activation mechanism. *Lipids*. 1990; 25:618–623. [PubMed: 2127820]
21. Serhan CN, Hamberg M, Samuelsson B. Trihydroxytetraenes: A novel series of compounds formed from arachidonic acid in human leukocytes. *Biochem Biophys Res Commun*. 1984; 118:943–949. [PubMed: 6422933]
22. Tornhamre S, Elmqvist A, Lindgren JA. 15-lipoxygenation of leukotriene A4: Studies of 12- and 15-lipoxygenase efficiency to catalyze lipoxin formation. *Biochim Biophys Acta, Mol Cell Biol Lipids*. 2000; 1484:298–306.
23. Chiang N, Arita M, Serhan CN. Anti-inflammatory circuitry: Lipoxin, aspirin-triggered lipoxins and their receptor ALX. *Prostaglandins, Leukotrienes Essent Fatty Acids*. 2005; 73:163–177.
24. Buckley CD, Gilroy DW, Serhan CN. Proresolving Lipid Mediators and Mechanisms in the Resolution of Acute Inflammation. *Immunity*. 2014; 40:315–327. [PubMed: 24656045]
25. Bonnans C, Gras D, Chavis C, Mainprice B, Vachier I, Godard P, Chanez P. Synthesis and anti-inflammatory effect of lipoxins in human airway epithelial cells. *Biomed Pharmacother*. 2007; 61:261–267. [PubMed: 17418999]
26. Serhan CN, Hamberg M, Samuelsson B, Morris J, Wishka DG. On the stereochemistry and biosynthesis of lipoxin B. *Proc Natl Acad Sci U S A*. 1986; 83:1983–1987. [PubMed: 3083410]
27. Fiore S, Serhan CN. Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. *J Exp Med*. 1990; 172:1451–1457. [PubMed: 2172436]
28. Romano M, Chen XS, Takahashi Y, Yamamoto S, Funk CD, Serhan CN. Lipoxin synthase activity of human platelet 12-lipoxygenase. *Biochem J*. 1993; 296:127–133. [PubMed: 8250832]
29. Haeggström JZ, Meijer J, Radmark O. Leukotriene A4: enzymatic conversion into 5,6-dihydroxy-7,9,11,14-eicosatetraenoic acid by mouse liver cytosolic epoxide hydrolase. *J Biol Chem*. 1986; 261:6332–6337. [PubMed: 3009453]
30. Ueda N, Yamamoto S, Fitzsimmons BJ, Rokach J. Lipoxin synthesis by arachidonate 5-lipoxygenase purified from porcine leukocytes. *Biochem Biophys Res Commun*. 1987; 144:996–1002. [PubMed: 3579953]
31. Ueda N, Yokoyama C, Yamamoto S, Fitzsimmons BJ, Rokach J, Oates JA, Brash AR. Lipoxin synthesis by arachidonate 12-lipoxygenase purified from porcine leukocytes. *Biochem Biophys Res Commun*. 1987; 149:1063–1069. [PubMed: 3122743]
32. Ringholz FC, Buchanan PJ, Clarke DT, Millar RG, McDermott M, Linnane B, Harvey BJ, McNally P, Urbach V. Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis. *Eur Respir J*. 2014; 44:394–404. [PubMed: 24696116]
33. Levy BD, Romano M, Chapman HA, Reilly JJ, Drazen J, Serhan CN. Human alveolar macrophages have 15-lipoxygenase and generate 15 (S)-hydroxy-5, 8, 11-cis-13-trans-eicosatetraenoic acid and lipoxins. *J Clin Invest*. 1993; 92:1572–1579. [PubMed: 8376607]
34. Ueda N, Kaneko S, Yoshimoto T, Yamamoto S. Purification of arachidonate 5-lipoxygenase from porcine leukocytes and its reactivity with hydroperoxyeicosatetraenoic acids. *J Biol Chem*. 1986; 261:7982–7988. [PubMed: 3086322]
35. Chavis C, Vachier I, Chanez P, Bousquet J. 5(S),15(S)-Dihydroxyeicosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors. *J Exp Med*. 1996; 183:1633–1643. [PubMed: 8666921]
36. Bryant RW, Simon TC, Bailey MJ. Role of glutathione peroxidase and hexose monophosphate shunt in the platelet lipoxygenase pathway. *J Biol Chem*. 1982; 257:14937–14943. [PubMed: 6816802]
37. Maas RL, Brash AR. Evidence for a lipoxygenase mechanism in the biosynthesis of epoxide and dihydroxy leukotrienes from 15 (S)-hydroperoxyeicosatetraenoic acid by human platelets and porcine leukocytes. *Proc Natl Acad Sci U S A*. 1983; 80:2884–2888. [PubMed: 6304687]


38. Lundberg U, Radmark O, Malmsten C, Samuelsson B. Transformation of 15-hydroperoxy-5,9,11,13-eicosatetraenoic acid into novel leukotrienes. *FEBS Lett.* 1981; 126:127–132. [PubMed: 7238859]
39. Serhan CN, Nicolaou KC, Webber SE, Veale CA, Dahlen SE, Puustinen TJ, Samuelsson B. LipoxinA4 stereochemistry and biosynthesis. *J Biol Chem.* 1986; 261:16340–16345. [PubMed: 3097008]
40. Ueda N, Yamamoto S. The 6R-oxygenase activity of arachidonate 5-lipoxygenase purified from porcine leukocytes. *J Biol Chem.* 1988; 263:1937–1941. [PubMed: 3338999]
41. Borgeat P, Samuelsson B. Metabolism of arachidonic acid in polymorphonuclear leukocytes. Structural analysis of novel hydroxylated compounds. *J Biol Chem.* 1979; 254:7865–7869. [PubMed: 468794]
42. Brash AR, Boeglin WE, Chang MS. Discovery of a second 15S-lipoxygenase in humans. *Proc Natl Acad Sci U S A.* 1997; 94:6148–6152. [PubMed: 9177185]
43. Wuest SJA, Crucet M, Gemperle C, Loretz C, Hersberger M. Expression and regulation of 12/15-lipoxygenases in human primary macrophages. *Atherosclerosis.* 2012; 225:121–127. [PubMed: 22980500]
44. Zhao H, Richards-Smith B, Baer AN, Green FA. Lipoxygenase mRNA in cultured human epidermal and oral keratinocytes. *J Lipid Res.* 1995; 36:2444–2449. [PubMed: 8656082]
45. Smyrniotis CJ, Barbour SR, Xia Z, Hixon MS, Holman TR. ATP Allosterically Activates the Human 5-Lipoxygenase Molecular Mechanism of Arachidonic Acid and 5(*S*)-Hydroperoxy-6(*E*), 8(*Z*), 11(*Z*), 14(*Z*)-eicosatetraenoic Acid. *Biochemistry.* 2014; 53:4407–4419. [PubMed: 24893149]
46. Lewis ER, Johansen E, Holman TR. Large Competitive Kinetic Isotope Effects in Human 15-Lipoxygenase Catalysis Measured by a Novel HPLC Method. *J Am Chem Soc.* 1999; 121:1395–1396.
47. Wecksler AT, Kenyon V, Garcia NK, Deschamps JD, van der Donk WA, Holman TR. Kinetic and Structural Investigations of the Allosteric Site in Human Epithelial 15-Lipoxygenase-2. *Biochemistry.* 2009; 48:8721–8730. [PubMed: 19645454]
48. Jameson JB, Kenyon V, Holman TR. A high-throughput mass spectrometric assay for discovery of human lipoxygenase inhibitors and allosteric effectors. *Anal Biochem.* 2015; 476:45–50. [PubMed: 25712042]
49. Van Os CPA, Rijke-Schilder GPM, Van Halbeek H, Verhagen J, Vliegthart JFG. Double dioxygenation of arachidonic acid by soybean lipoxygenase-1: Kinetics and regio-stereo specificities of the reaction steps. *Biochim Biophys Acta, Lipids Lipid Metab.* 1981; 663:177–193.
50. Frisch, M., Trucks, G., Schlegel, H., Scuseria, G., Robb, M., Cheeseman, J., Scalmani, G., Barone, V., Mennucci, B., Peterson, G., Nakatsuji, H., Caricato, M., Li, X., Hratchian, H., Izmaylov, A., Bloino, J., Zheng, G., Sonnenberg, J., Hada, M., Ehara, M., Toyota, K., Fukuda, R., Hasegawa, J., Ishida, M., Nakajima, T., Honda, Y., Kitao, O., Nakai, H., Vreven, T., Montgomery, JA., Jr, Peralta, J., Ogliaro, F., Bearpark, M., Heyd, J., Brothers, E., Kudin, K., Staroverov, V., Kobayashi, R., Normand, J., Raghavachari, K., Rendell, A., Burant, J., Iyengar, S., Tomasi, J., Cossi, M., Rega, N., Millam, J., Klene, M., Knox, J., Cross, J., Bakken, V., Adamo, C., Jaramillo, J., Gomperts, R., Stratmann, R., Yazyev, O., Austin, A., Cammi, R., Pomelli, C., Ochterski, J., Martin, R., Morokuma, K., Zakrzewski, V., Voth, G., Salvador, P., Dannenberg, J., Dapprich, S., Daniels, A., Farkas, O., Foresman, J., Otriz, J., Cioslowski, J., Fox, D. Gaussian 09. Gaussian, Inc.; Wallingford, CT: 2009.
51. Becke AD. Density-functional exchange-energy approximation with correct asymptotic behavior. *Phys Rev A: At, Mol, Opt Phys.* 1988; 38:3098–3100.
52. Lee C, Yang W, Parr RG. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. *Phys Rev B: Condens Matter Mater Phys.* 1988; 37:785–789.
53. Miehlich B, Savin A, Stoll H, Preuss H. Results obtained with the correlation energy density functionals of Becke and Lee, Yang and Parr. *Chem Phys Lett.* 1989; 157:200–206.
54. Krishnan R, Binkley JS, Seeger R, Pople JA. Self-consistent molecular orbital methods. XX. A basis set for correlated wave functions. *J Chem Phys.* 1980; 72:650–654.

55. Bryant RW, Bailey MJ, Schewe T, Rapoport SM. Positional specificity of a reticulocyte lipoxigenase. Conversion of arachidonic acid to 15-S-hydroperoxy-eicosatetraenoic acid. *J Biol Chem.* 1982; 257:6050–6055. [PubMed: 6804460]
56. Kuhn H, Barnett J, Grunberger D, Baecker P, Chow J, Nguyen B, Bursztyjn-Pettegrew H, Chan H, Sigal E. Overexpression, purification, and characterization of human recombinant 15-lipoxygenase. *Biochim Biophys Acta, Lipids Lipid Metab.* 1993; 1169:80–89.
57. Joshi N, Hoobler EK, Perry S, Diaz G, Fox B, Holman TR. Kinetic and Structural Investigations into the Allosteric and pH Effect on the Substrate Specificity of Human Epithelial 15-Lipoxygenase-2. *Biochemistry.* 2013; 52:8026–8035. [PubMed: 24171444]
58. Hoobler EK, Holz C, Holman TR. Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases. *Bioorg Med Chem.* 2013; 21:3894–3899. [PubMed: 23669189]
59. Abramovitz M, Wong E, Cox ME, Richardson CD, Li C, Vickers PJ. 5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. *Eur J Biochem.* 1993; 215:105–111. [PubMed: 8344271]
60. Rakonjac M, Fischer L, Provost P, Werz O, Steinhilber D, Samuelsson B, Radmark O. Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 production. *Proc Natl Acad Sci U S A.* 2006; 103:13150–13155. [PubMed: 16924104]
61. Gerstmeier J, Weinigel C, Barz D, Werz O, Garscha U. An experimental cell-based model for studying the cell biology and molecular pharmacology of 5-lipoxygenase-activating protein in leukotriene biosynthesis. *Biochim Biophys Acta, Gen Subj.* 2014; 1840:2961–2969.
62. Shimizu T, Radmark O, Samuelsson B. Enzyme with dual lipoxygenase activities catalyzes leukotriene A4 synthesis from arachidonic acid. *Proc Natl Acad Sci U S A.* 1984; 81:689–693. [PubMed: 6322165]
63. Radmark O, Malmsten C, Samuelsson B. Leukotriene A: stereochemistry and enzymatic conversion to leukotriene B. *Biochem Biophys Res Commun.* 1980; 92:954–961. [PubMed: 6244821]
64. Radmark O, Shimizu T, Jornvall H, Samuelsson B. Leukotriene A4 hydrolase in human leukocytes: purification and properties. *J Biol Chem.* 1984; 259:12339–12345. [PubMed: 6490615]
65. Fitzpatrick FA, Morton DR, Wynalda MA. Albumin stabilizes leukotriene A4. *J Biol Chem.* 1982; 257:4680–4683. [PubMed: 6279645]
66. Ghosh J, Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. *Proc Natl Acad Sci U S A.* 1998; 95:13182–13187. [PubMed: 9789062]
67. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. *Cancer.* 2001; 91:737–743. [PubMed: 11241241]
68. Cristol JP, Sirois P. Comparative activity of leukotriene D4, 5,6-dihydroxy-eicostetraenoic acid, and lipoxin A on guinea pig lung parenchyma and ileum smooth muscle. *Res Commun Chem Pathol Pharmacol.* 1988; 59:423–426. [PubMed: 3363228]
69. Muller A, Rechencq E, Kugel C, Lellouche JP, Beaucourt JP, Niel G, Girard JP, Rossi JC, Bonne C. Comparative biological activities of the four synthetic (5,6)-dihete isomers. *Prostaglandins.* 1989; 38:635–644. [PubMed: 2633210]







**Figure 1.** h15-LOX-2 converts 5-HPETE to 5,15-diHPETE. (A) Total ion count (TIC) chromatogram of h15-LOX-2's reaction with 5-HPETE, which displays ions with a parent  $m/z$  of 335.2. The large peak has a retention time of 8.9 min and a  $\lambda_{\text{max}}$  value of 245 nm, as seen in the UV-vis spectra of the peak (inset), which matches the 5,15-diHETE standard. (B) Mass spectrum of the peak at 8.9 min. The diagnostic peaks for 5,15-diHETE are bolded and boxed.



**Figure 2.** Structures of *in silico* models and dehydrogenation mechanisms. (1) Model **m1** represents arachidonic acid's conjugated system and the two hydrogen atom abstractions A and B that result in two radical structures with similar energies. (2) Model **m2** represents 5-HPETE and 15-HPETE's conjugated system and the two hydrogen atom abstractions A and B that result in two radical structures with different energies. (3) Model **m3** represents 5,15-diHPETE and the resulting low energy radical structure from a C10 hydrogen atom abstraction.




**Figure 3.** h15-LOX-2 cannot synthesize lipoxins from the 5,15-diHPETE intermediate. A TIC chromatogram of the reactions of h15-LOX-2 (solid line) and h15-LOX-1 (dashed line) with 5,15-diHPETE, displaying ions with a parent  $m/z$  of 351.2. In the h15-LOX-1 reactions, LipoxinB<sub>4</sub> and -A<sub>4</sub> peaks were confirmed with retention times, UV-vis spectra, and MS spectra as compared to the standards. The tiny peak at the retention time of LxA<sub>4</sub> in the h15-LOX-2 reaction was not LxA<sub>4</sub>, as determined by its MS<sup>2</sup> spectra. Thus, no lipoxin peaks were seen for h15-LOX-2.




**Figure 4.**

h15-LOX-2 converts 5*S*,6*R*-diHETE to LipoxinA<sub>4</sub>. (A) A TIC chromatogram of h15-LOX-2's reaction with 5*S*,6*R*-diHETE, displaying ions with a parent  $m/z$  of 351.2. The large peak has a retention time of 3.9 min and a  $\lambda_{\text{max}}$  value of 302 nm, as seen in the UV-vis spectrum of the peak (inset), which matches the LipoxinA<sub>4</sub> standard. (B) Mass spectrum of the peak at 3.9 min. The diagnostic peaks for LipoxinA<sub>4</sub> are bolded and boxed.



### Scheme 1. Biosynthetic Routes to Lipoxins<sup>a</sup>

<sup>a</sup>LipoxinA<sub>4</sub>, LipoxinB<sub>4</sub>, and their respective isomers can arise from arachidonic acid (AA) through the pathways laid out in this scheme. The names of major products are boxed, such as LTA<sub>4</sub> and LxB<sub>4</sub>. Enzymes are listed above the arrows of the reactions performed. The arrows with no enzyme listed are hydrolysis reactions that either are catalyzed by soluble epoxide hydrolase or are nonenzymatic, as indicated by the products. The numerous products observed that arise from nonenzymatic hydrolysis, indicated by a single asterisk, are listed in Figure S2. Reactions that h15-LOX-2 can perform are indicated by two asterisks; however, these reactions can also be performed by h15-LOX-1. Please note that this scheme has been simplified. For example, the required reductions of the hydroperoxy moieties to hydroxyl moieties are typically performed by glutathione peroxidase. These reactions, along with the 14*R*-oxygenase and 6*R*-oxygenase activities of h12-LOX and h5-LOX, have been excluded for clarity.



**Scheme 2. Positional Specificity of 15-Lipoxygenases<sup>a</sup>**

<sup>a</sup>(A) h15-LOX-2 has demonstrated the ability to only abstract the hydrogen atom at C13 and allow oxygen attack at C15 (solid arrows) of arachidonic acid. (B) h15-LOX-1 can abstract a hydrogen atom from C13 and oxygenate at C15 as well but also abstracts the C10 hydrogen atom and facilitates oxygen attack at the C12 position (dashed arrows).



**Table 1**

Steady-State Parameters for h15-LOX-2 Hydroperoxidation of 5-HETE and 5-HPETE

	relative $k_{\text{cat}}^a$	$K_{\text{m}}$ ( $\mu\text{M}$ )	relative $k_{\text{cat}}/K_{\text{m}}^a$
AA	$1.00 \pm 0.04$	$4.0 \pm 0.6$	$1.0 \pm 0.1$
5-HETE	$2.1 \pm 0.2$	$33 \pm 5$	$0.25 \pm 0.01$
5-HPETE	$1.5 \pm 0.1$	$19 \pm 2$	$0.31 \pm 0.02$

<sup>a</sup>All  $k_{\text{cat}}$  and  $k_{\text{cat}}/K_{\text{m}}$  values are relative to the  $k_{\text{cat}}$  and  $k_{\text{cat}}/K_{\text{m}}$  values of AA, which are  $0.64 \pm 0.02 \text{ s}^{-1}$  and  $0.16 \pm 0.02 \mu\text{M}^{-1} \text{ s}^{-1}$ , respectively.